AstraZeneca is in preliminary talks to acquire $Bristol-Myers Squibb(BMY)$ in a potential $400 billion mega-merger. While unconfirmed talks spark immediate speculative upside for BMY, regulatory scrutiny over overlapping oncology pipelines means traders should expect elevated volatility rather than a guaranteed buyout. Thank you for your LIKE and FOLLOW. I heard you, TIGERSSS. Option Comm Free Vouchers are available for you. Contact me before it ends. IF YOU ALREADY OWN THE SHARES If you hold 100 or more shares of BMY, you can consider selling covered calls (selling the right for someone else to buy your shares at a specified target price to collect upfront income) out-of-the-money. With BMY trading near $65.31 and underlying implied volatility (IV